Newegg Launches 11th Annual FantasTech Sale Starting July 7: Thousands of Tech Deals and FantasTech Price Protection
A special FantasTech deal includes a $599.99 ABS Gaming PC equipped with an NVIDIA GeForce RTX 5060 GPU, available while supplies last.
Share
This year, FantasTech Price Protection is back and earlier than ever, giving customers peace of mind while shopping. Products displaying the FantasTech Price Protection badge are eligible for automatic refunds if their price drops later on Newegg. For the first time, select products in Newegg's Independence Day Sale and Canada Day Sale will also be covered under this program.
FantasTech Sale Schedule
June 30 – July 6: Independence Day & Canada Day Sale
Includes early FantasTech deals with Price Protection
July 7 – July 13: FantasTech Sale
Shoppers will find major discounts on: Desktop PCs, laptops, PC components, NAS and storage, peripherals, servers, software, gaming products, collectibles, home and office goods, security equipment, gift cards, and more.
A special FantasTech deal includes a $599.99 ABS Gaming PC equipped with an NVIDIA GeForce RTX 5060 GPU, available while supplies last.
No Membership Required
All customers on Newegg.com and Newegg.ca are automatically enrolled in the FantasTech Price Protection program during the eligible period.
'With the recent launches of next-generation GPUs and CPUs, it's the perfect time to have one of our largest sales of the year,' said Steven Chien, VP of Product Management at Newegg. 'Any customer can build the PC of their dreams while leveraging our best savings with no membership required.'
About FantasTech Price Protection
Customers who purchase an eligible product with the FantasTech Price Protection badge now through July 6, 2025, will receive an automatic refund if the item's price drops on Newegg.com and Newegg.ca before July 13, 2025.
No need to track prices or file claims
Refunds will be issued to the original payment method by July 22, 2025
Email confirmations will be sent once processed
Newegg's internal systems will check for price drops on all eligible purchases within the program period.
How to Shop FantasTech
Shoppers can access deals on the homepage and use Newegg's suite of tools:
AI Shopping Assistant (found on every product page)
PC Builder for custom part selection
Gaming PC Finder to match games with PC performance
Server Configurator for IT professionals
NAS Builder to accommodate all storage needs
Gamer Community (Beta) to engage with other shoppers and gamers
Disclaimers
Prices and availability are subject to change without notice. Products from third-party brands are sold by Newegg but manufactured and warrantied by their respective companies. For the latest updates, visit Newegg.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
44 minutes ago
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of July 3, 2025: (1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Business Insider
an hour ago
- Business Insider
Despite all the drama, trade uncertainty hasn't really hurt economic growth, Goldman Sachs says
President Donald Trump's new policies may be upending the global trade order, but so far, they're not hitting the economy hard, wrote Goldman Sachs analysts. "There are very few signs that uncertainty is taking a toll on activity," analysts at Goldman Sachs wrote in a Thursday note. Even though the analysts had expected Trump's second term to slow economic activity, the numbers tell a different story. Since late 2024, investment, factory hiring, consumer spending, and broader economic activity have all stayed resilient across major developed and emerging markets. In fact, growth forecasts for both the second quarter and this full year have actually improved from earlier, more pessimistic calls. The analysts pointed out that in most economies, trade-exposed investment accounts for a small share of GDP, so the impact may just be "too small to see." New factory investment, especially in emerging markets, has dipped, but this accounts for just 0.2 to 0.3 percentage points of GDP in major economies. The analysts also wrote that uncertainty usually bites hardest when financial conditions tighten. But global liquidity has actually improved since the start of the year, making it easier for businesses to borrow money and invest. Meanwhile, activity and investment expectations that dipped in April — which coincided with Trump's "Liberation Day" announcement — have already bounced back on improved tariff news. "As such, while we continue to expect that tariffs will slow activity later this year, we expect this will be mostly driven by the direct impacts of tariffs rather than uncertainty around trade policy," they added. Goldman's report came as the US posted better-than-expected employment data in June. The economy added 147,000 jobs, and unemployment fell from 4.2% to 4.1%. Investor sentiment is upbeat, with the S&P 500 and the Nasdaq at record highs. To be sure, trade policy uncertainty remains high by historical standards, with Goldman's uncertainty index spiking after Trump's election. But that uncertainty has eased in recent months as Trump negotiates new trade deals. Some businesses did rush to ship goods to the US ahead of potential tariffs, a phenomenon known as "front-loading," which may have helped mask some issues. But even after controlling for that, Goldman analysts found little evidence of an "uncertainty drag" on growth. There were also few differences between economic activities in countries that did and didn't boost exports to the US this spring. "The uncertainty drag, therefore, appears smaller than feared," they wrote.
Yahoo
2 hours ago
- Yahoo
Prediction: This Growth Stock Will Skyrocket in the Second Half of 2025
Micron Technology has clocked impressive gains so far in 2025, and it looks set to fly higher in the second half of the year as well. The company's latest quarterly results make it clear that it is benefiting big time from fast-growing demand for memory chips used in various applications. Micron's solid growth potential and attractive valuation make the stock a no-brainer buy right now, considering the potential upside it could deliver. 10 stocks we like better than Micron Technology › Memory specialist Micron Technology (NASDAQ: MU) has been delivering terrific growth in recent quarters thanks to booming demand for its chips deployed in data centers, smartphones, and personal computers (PCs), which explains why the stock has clocked solid gains of 46% so far this year. Micron released its fiscal 2025 third-quarter results (for the three months ended May 29) on June 25. A closer look at the company's numbers and guidance suggests that its rally is here to stay in the second half of the year. Let's look at the reasons why investors can expect Micron stock to deliver more upside for the rest of the year as well. Micron's fiscal Q3 revenue shot up 37% year over year to $9.3 billion, while its adjusted earnings more than tripled to $1.91 per share. The numbers crushed Wall Street's expectations of $1.60 per share in earnings on revenue of $8.86 billion. Micron CEO Sanjay Mehrotra remarked on the latest earnings conference call that its data center revenue more than doubled from the year-ago period and hit record levels last quarter. This terrific growth was driven by the healthy demand for Micron's high-bandwidth memory (HBM) chips that are integrated with AI accelerators from the likes of Nvidia and AMD. Micron management points out that it is shipping its HBM chips in high volumes to four customers right now, who are integrating them with both graphics cards and custom AI processors. Importantly, Micron is not resting on its laurels and is focused on further improving the performance of its HBM chips. The company claims its next-generation HBM4 chips, which will succeed the HBM3E offerings, will pack 60% more performance while reducing power consumption by 20%. The company has already provided samples of HBM4 to customers and expects to start the volume production of this product in 2026. Micron's focus on pushing the envelope on the product development front is the right thing to do, considering that the HBM market is set to take off impressively in the long run. Bloomberg Intelligence estimates that the HBM market could generate annual revenue of $130 billion by 2030. That would be a huge jump over the $4 billion revenue this segment clocked in 2023. Micron, therefore, still has massive room for growth in this segment, both in the short and long run. The strong momentum provided by the HBM business tells us why the company's guidance for the current quarter points toward another solid increase in its top and bottom lines. Micron has guided for $10.7 billion in revenue for the fiscal fourth quarter, which would be a 38% increase over the prior-year period. That would be a slight improvement over the revenue growth it reported in the previous quarter. Meanwhile, Micron's forecast of $2.50 per share in earnings for the current quarter suggests its bottom line will more than double from the year-ago period's reading of $1.18 per share. The stronger growth in Micron's earnings can be attributed to a favorable memory pricing environment. Memory manufacturers such as Micron have been increasing the prices of chips on account of solid HBM demand and supply constraints. According to TrendForce, the average price of dynamic random access memory (DRAM) chips increased in the range of 3% to 8% in the second quarter, owing to an increase in sales of HBM, along with an improvement in the demand for mobile and consumer-oriented DRAM chips. Looking ahead, Micron management estimates that adoption of AI-enabled personal computers (PCs) and smartphones will contribute to the company's growth in the coming quarters. So Micron's catalysts are likely to get stronger as the year progresses, and that could pave the way for more upside in the second half of 2025 and beyond. We have already seen how rapidly Micron's revenue and earnings are growing. However, the company's valuation suggests that it is extremely undervalued, considering the phenomenal growth it's been clocking. Micron has a trailing price-to-earnings ratio of 22, while the forward earnings multiple is even more attractive at 11. The company is on track to end the current fiscal year with adjusted earnings of $7.76 per share (based on its guidance of $2.50 per share for fiscal Q4 and cumulative earnings of $5.26 per share in the first three quarters of the year). That would be a huge increase over its fiscal 2024 earnings of $1.30 per share. What's more, analysts are expecting a 54% spike in Micron's earnings in the next fiscal year to $12.05 per share. If the stock maintains its trailing earnings multiple of 23 after a year, its stock price could hit $265. That would be more than double current levels. As such, Micron's latest quarterly results should give its rally a nice shot in the arm in the second half of the year, as the market could reward its terrific growth with a richer valuation, while the projected earnings growth for the next fiscal year indicates that it could continue soaring in 2026 as well. Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool has a disclosure policy. Prediction: This Growth Stock Will Skyrocket in the Second Half of 2025 was originally published by The Motley Fool
